Dr Jane Sosabowski

BSc (Hons), MSc, PhD
Reader in Preclinical Molecular Imaging
Group Leader
Research Focus

My main interests are in radiopharmaceutical development and the use of pre-clinical molecular imaging in drug development, especially biopharmaceuticals.

Key Publications

Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. J Nucl Med (2009) 50, 2082-9. PMID: 19910426

Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nature Protocols (2006) 1, 972-976. PMID: 17406332

Insertion of a lysosomal enzyme cleavage site into the sequence of a radiolabeled neuropeptide influences cell trafficking in vitro and in vivoCancer Biother Radiopharm (2010) 25, 89-95. PMID: 20187801

Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study. Eur J Pharm Sci (2007) 31, 102-11. PMID: 17387005

Major Funding
  • 2018-2021- Barts Charity, Development of a Gallium-68 PET Clinical Imaging Service, £499,993.61

I am particularly interested in imaging radiolabelled peptides and proteins for use in diagnosis and therapy of cancer.  These might be radiolabelled with positron emitters such as 68Ga or 64Cu in order to carry out PET imaging, 111In or 99mTc for SPECT imaging or with therapy radioisotopes such as 90Y and 177Lu.

The lab has a long-standing interest in imaging CCK-2 and GRP receptors which are overexpressed in a number of tumour types.

Drug development studies entail using imaging to show specific tissue targeting of small antibodies.  The aim is to use these targeting proteins to carry a therapeutic payload to the site of disease and this work is carried out in collaboration with GSK. We also use radioactive probes such as 18F-FDG and 18F-FLT to monitor response to treatment in vivo.

Major Funding
  • 2018-2021- Barts Charity, Development of a Gallium-68 PET Clinical Imaging Service, £499,993.61
  • 2011-2015- GlaxoSmithKline Research & Development, Evaluation of DAB's in vivo as part of a technology development, £336,608
Recent Publications

DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. Klingler M, Summer D, Rangger C et al. J Nucl Med (2019) 60(2) 1010-1016

New Developments in Imaging Cell-Based Therapy. Martinez O, Sosabowski J, Maher J et al. J Nucl Med (2019) 60(2) 730-735

Rational design, synthesis and preliminary evaluation of novel fusarinine C-based chelators for radiolabeling with Zirconium-89 Zhai C, He S, Ye Y et al. Biomolecules (2019) 9(7)

Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer. Deshayes E, Ladjohounlou R, Le Fur P et al. J Nucl Med (2018) 59(2) 1234-1242

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting. Klingler M, Decristoforo C, Rangger C et al. Theranostics (2018) 8(1) 2896-2908

Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells. Emami-Shahri N, Foster J, Kashani R et al. Nature Communications (2018) 9(1) 1081-1081

Anesthesia and monitoring of animals during MRI studies Tremoleda JL, Macholl S, Sosabowski JK (2018) 1718(7) 423-439

Functionalised carbon nanotubes enhance brain delivery of amyloid-targeting pittsburgh compound b (Pib)-derived ligands Costa PM, Wang JTW, Morfin JF et al. Nanotheranostics (2018) 2(7) 168-183

Investigating in vitro and in vivo αvβ6 integrin receptor-targeting liposomal alendronate for combinatory γδ T cell immunotherapy Hodgins NO, Al-Jamal WT, Wang JTW et al. Journal of Controlled Release (2017) 256(7) 141-152

High-throughput high-volume nuclear imaging for preclinical in vivo compound screening§. Macholl S, Finucane CM, Hesterman J et al. EJNMMI Res (2017) 7(1) 33-33

For additional publications, please click here

Postdoctoral Researchers
Dr Julie FosterDr Roxana Kashani

PhD Students
Mr Joseph Brook


I graduated with a BSc (Hons) in Chemistry from University of Natal, Durban, South Africa and went on carry out an MSc by research into the Photochemistry of Sunscreen Constituents at same university.

I then moved to the UK to the Joint Department of Physics at the Institute of Cancer Research in Sutton, Surrey and completed my PhD looking at Development of PET radiotracers for the in vivo assessment of multidrug resistance. I then moved to the Nuclear Medicine Research Laboratory at Barts and the London School of Medicine and Dentistry to carry out a post doc under Prof Stephen Mather.

With the advent of pre-clinical imaging systems this lab developed into the Cancer Imaging Laboratory.